Synchron Raises $200M Series D to Advance Brain-Computer Interface Technology
Synchron announced a $200 million Series D funding round aimed at accelerating the commercialization of its Stentrode brain-computer interface (BCI) system. Headquartered in New York, the company will allocate these funds to expand pivotal trials and speed up the launch of Stentrode.
Funding Details and Strategic Plans
The new financing brings Synchron’s total funding to $345 million. The company plans to increase hiring across engineering, neuroscience, and operations teams to support its goals. Additionally, Synchron aims to develop next-generation BCIs to further advance brain-machine interaction.
Development and Expansion Efforts
- An expanding Cognitive AI division in New York will train models that decode thought in real time from brain data.
- A new engineering hub in San Diego has been established to develop advanced brain interface technology.
Investment Participation
The Series D was led by Double Point Ventures. Existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS also participated. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
About Stentrode Technology
Stentrode is uniquely implanted via an endovascular approach, entering the brain’s blood vessels to detect motor intention.
Synchron states it is "the only BCI using blood vessels to capture brain signals."
The implant is positioned on the motor cortex surface through the jugular vein, enabling direct signal capture for interpreting motor commands.
Author’s Summary
Synchron’s $200M funding will fast-track pivotal trials and new technologies, cementing its unique blood-vessel-based brain-computer interface approach.